CDK9-IN-25

• Description:

  CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM) . CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM) [1].

• UNSPSC:

  12352005

• Target:

  CDK; SARS-CoV; Virus Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-25.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(C)(C)NC1=C(N=C2N1C=CN=C2)C3=CC(F)=NC=C3

• Molecular Formula:

  C15H16FN5

• Molecular Weight:

  285.32

• References & Citations:

  [1]Alsfouk AA, et al. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel) . 2023 Jul 18;16 (7) :1018..

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported